HealthHighlight

Could a Pill Put the Brakes on Aging?

311

By By Matt Smith

The No. 1 risk factor for all the big diseases — cancer, heart disease, Alzheimer’s — is aging.

But instead of treating the diseases, could a drug treat the aging process itself?

That’s the idea behind a growing area of research drawing extensive support from both government and private donors, including millions from Silicon Valley executives like Microsoft co-founder Paul Allen and venture capitalist Peter Thiel. While federal science agency budgets have struggled in the past decade, funding at the National Institute on Aging has risen more than 50% since 2007.

Researchers are seeking a drug to push back the most serious consequences of aging — and keep people healthy, active, and alert years longer, a notion they call “health span.”

“I’m not interested in creating a population that lives to be 200, because that would be a problem for the world we live in,” says Corinna Ross, PhD, a biologist at Texas A&M University in San Antonio. “But if we can keep people out of nursing home care and reduce the number of Alzheimer’s and Parkinson’s patients, that would be ideal.”

What scientists know about aging has advanced sharply in the past 2 decades as they learn more about what drives the aging process within cells. With the race on to find an anti-aging pill, two of the most promising ones are drugs that already exist: metformin and rapamycin.

Metformin

Doctors have prescribed metformin, the most common drug to treat type 2 diabetes, for about 60 years. But it’s received new attention as a possible anti-aging drug after researchers in Britain found that people with diabetes who took it outlived some of their peers who did not have the disease by 15%.

“They compared them to a whole bunch of people who were matched for weight and smoking and [other factors] but who didn’t have diabetes,” says Steven Austad, PhD, chairman of the biology department at the University of Alabama at Birmingham. “It turned out the diabetics on metformin were living longer than the non-diabetics who were not on metformin. … It was very, very intriguing.”

Austad is a bio-gerontologist and scientific director of the American Federation for Aging Research. The organization is trying to raise about $65 million in federal and private funding for what Austad says would be the first human trial of an anti-aging drug. Researchers would give the drug to people ages 65 to 80 with no chronic conditions, then wait to see how long it takes until their next major health problem shows up, Austad says.

Scientists believe the drug works in the mitochondria, the powerhouses in the body’s cells that convert sugars like glucose into energy. Austad says metformin makes those powerhouses run more efficiently, reducing the release of substances known as free radicals. Free radicals can damage cells, hurting their ability to reproduce and causing defects.

Metformin may also activate an enzyme that controls the body’s demand for energy. Austad says that activation mimics the effect of a low-calorie diet, something researchers say can extend life span in laboratory animals.

Rapamycin

Biologist Ross is one of several scientists who have looked into the potential life-extending effects of rapamycin. This potent drug, also known as sirolimus and the brand name Rapamune, is most often used in chemotherapy and to keep the bodies of transplant patients from rejecting a new organ. Studies show that the drug can extend life span in mice, roundworms, and monkeys known as marmosets.

Like metformin, rapamycin works on a cell’s mitochondria, where it may change how cells burn glucose, Ross says. Researchers suspect rapamycin can keep the mitochondria running smoothly longer.

“The image I teach to my students is the idea of a factory running out of control, and it’s just spewing stuff out the windows, and you’ve got a negative cascade effect,” Ross says. Preventing mitochondria running wild and burning out can head off effects like inflammation — a common contributor to age-related diseases.

Rapamycin “works in everything from yeast to mice. It works in multiple mouse strains and backgrounds. It works in both sexes,” says biologist Brian Kennedy, PhD former president of the Buck Institute for Research on Aging in Novato, CA. “I think it’s really exciting.”

For example, the drug has extended life span in mice by 30% to 50%, Austad says. And multiple animal studies show its promise for protecting against cancer and heart disease, as well as degenerative brain disorders like Alzheimer’s.

But it has some powerful side effects.

Rapamycin can cause mouth sores, cataracts, and diabetes. It can also raise the risks of infection, bleeding, and some types of cancers, such as skin cancer. It can cause high blood pressure, fever, and anemia.

Kennedy says much of the rapamycin research under way is aimed at figuring out how to reduce its side effects. What researchers know about the drug’s side effects comes from people who already have serious health problems and who usually take it in combination with other drugs. But they don’t know whether those same issues would happen in healthier people taking the drug on its own.

So while rapamycin appears to produce more dramatic results, metformin is likely to get a clinical trial in humans first, Kennedy says.

“Metformin has been in millions of people. It’s pretty safe as drugs go,” he says. And as doctors and scientists delve deeper into anti-aging research, “The last thing we want is a drug that’s going to cause toxicity and have something like that happen, because that’s going to set the whole deal back.”

Ross’s marmoset study, published in 2015, was the first to look at rapamycin’s side effects in healthy primates. Like humans, marmosets have a higher risk of heart problems and metabolic illnesses when they’re obese. The study found no notable metabolic problems in a group of the monkeys who received rapamycin in human-equivalent doses for a year, and they lost significant amounts of body fat in the early months.

Beyond metformin and rapamycin, other research has looked at the potential anti-aging role of various drugs, hormones, and food compounds, with mixed or uncertain results:

Resveratrol, a compound found in grapes and nuts, may reduce stress that leads to cell aging. Research shows it can extend life span in yeast, worms, and fish, but these effects haven’t been demonstrated in humans yet.
Acarbose, a diabetes drug that can block the body’s absorption of carbohydrates, showed promise in male mice, but did little for females, Kennedy says.

A hormone called 17-alpha-estradiol, a type of the female hormone estrogen, has shown “great promise” in extending longevity in mice, Austad says. But its side effects haven’t been investigated enough to know what risks they may pose.

Kennedy says being able to prevent some of the most debilitating age-related illnesses holds out the hope of a better life.

“We’re better at keeping people alive with various diseases of aging, but we rarely bring them back to full health,” he says. “I think it’s going to be much better for the quality of life of the individual, and much better economically, if we can just keep them from getting sick in the first place.”

Leave a comment

Related Articles

Rodri Brushes Off Vinicius, Real Madrid at Ballon d’Or ceremony

Recently crowned 2024 Ballon d’Or winner Rodri has downplayed the absence of...

Super Eagles Land in Abidjan, Gear Up for Benin Republic Clash

The Nigerian national football team, the Super Eagles, has arrived in Abidjan,...

Nigeria signs $1.2bln deal with CNCEC to revive aluminium smelter

Nigeria has taken a significant step towards reviving its dormant aluminium smelter...

VP Shettima Arrives in Benin City for Edo Governor’s Inauguration

Vice President Kashim Shettima has arrived in Benin City, Edo State capital,...

Breaking: Powerful explosion rocks Jos, many people feared dead

A devastating explosion shook the city of Jos on Tuesday morning, sending...

NNPC Ltd. boss, Mele Kyari, thrashes allegation of sabotaging Dangote Refinery as baseless

Mr. Mele Kyari, the Group Chief Executive Officer of the Nigerian National...

Infanticide: US places $25,000 bounty on fleeing Nigerian parent

The United States of America has offered a $25,000 reward for anyone...

Tinubu, Abiodun, Sanwo-Olu, others extol Pastor Tunde Bakare at 70

Pastor Tunde Bakare, the founder of Citadel Global Community Church, is a...

NNPC Ltd. Unveils Plan to Resolve Nigeria’s Energy Trilemma

Nigerian National Petroleum Company Limited (NNPC Ltd) Group CEO, Mr. Mele Kyari,...

Breaking: IPMAN Secures Direct Supply Deal with Dangote Refinery, Promises Steady, Affordable Fuel Nationwide

The Independent Petroleum Marketers Association of Nigeria (IPMAN) has announced a landmark...

“Operation Sweep”, FCT demolition squad, faces backlash from residents, Wike reacts

The recent demolition exercise by “Operation Sweep”, a task force set up...

Nov. 16 Ondo guber poll: Sensitive election materials arrive

Ahead of the Saturday, October 16 governorship poll in Ondo State, sensitive...

China’s imports from Nigeria soar to $15.1bln, 36.1% increase

China’s imports from Nigeria have reached an all-time high of $15.1 billion...

Vandals destroy TCN towers, disrupt power supply in Abuja

The Transmission Company of Nigeria (TCN) has reported a fresh attack on...

Amid opposition, Kano Rep. Jibrin promises to push Tinubu’s tax reform bills through in NASS

In spite of growing opposition to President Bola Tinubu’s controversial tax reform...

FCT Police bust notorious car theft syndicate, arrest suspect, recover 3 vehicles

The Federal Capital Territory (FCT) Police has confirmed the arrest of a...

Osimhen’s Brace Powers Galatasaray to 3-2 Win Over Samsunspor

Nigerian striker Victor Osimhen led Galatasaray to a thrilling 3-2 victory over...

Amotekun, Vigilante groups barred from Ondo gov. election – IGP Egbetokun

The Inspector-General of Police Kayode Egbetokun has banned Amotekun, Vigilante Groups, and...

NPA firefighters extinguish APMT crane fire, no fatalities recorded

The Nigerian Ports Authority (NPA) firefighters, with assistance from other sister agencies,...

Nigeria’s Okonjo-Iweala set to serve second term as WTO DG unopposed

The World Trade Organization (WTO) has confirmed that Dr. Ngozi Okonjo-Iweala will...